Safety and efficacy of sitagliptin plus granulocyte-colony stimulating factor [lenograstim] in patients suffering from acute myocardial infarction

Trial Profile

Safety and efficacy of sitagliptin plus granulocyte-colony stimulating factor [lenograstim] in patients suffering from acute myocardial infarction

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lenograstim (Primary) ; Sitagliptin (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms SITAGRAMI
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 25 Jun 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top